Login / Signup

Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States.

Joshua T SmithFernando S VelayosFang NiuVincent LiuThomas DelateSuresh PolaKim LeRita L Hui
Published in: Crohn's & colitis 360 (2021)
Initiation of infliximab-dyyb was non-inferior to infliximab among biologic-naive patients with IBD in an US integrated healthcare delivery system.
Keyphrases
  • ulcerative colitis
  • healthcare
  • patients with inflammatory bowel disease
  • rheumatoid arthritis
  • hiv infected
  • antiretroviral therapy